2013


To access this material please log in or register

Register Authorize
2013/№3

Use of mildronate for improving adaptation to extreme climatic conditions (heat exposure) in patients with moderate and high risk of cardiovascular complications

Smirnova M. D., Svirida O. N., Vitsenya M. V., Tikhaze A. K., Konovalova G. G., Lankin V. Z., Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: adaptation to heat, heat, mildronate, cardiovascular diseases

DOI: 10.18087/rhj.2013.3.1843

Background. Since long-term exposure to severe climate may play a role of an independent stress factor, it seems relevant to study the efficacy of additional preventive administration of medicines increasing stress resistance of the body (adaptogens). Aim. To evaluate the effect of mildronate on the cardiovascular system, psychological status and quality of life in patients with moderate and high risk of cardiovascular complications in severe climatic conditions (summer heat). Material and methods. Study included 56 patients aging 38–75 years with moderate (22 patients) and high / very high (34 patients) risk of cardiovascular complications. The patients were randomized to two groups, the active management group where the patients received mildronate in addition to their standard therapy for three summer months, and the control group. Office BP, plasma levels of potassium, sodium, malonic dialdehyde (MDA), and red cell superoxide dismutase (SOD) activity were measured. The MDA / SOD ratio was computed based on the test results. A visual analogue scale (VAS) was used for evaluation of quality of life. Results. Patients receiving mildronate had lower SBP and heart rate during hot weather, higher sodium level at visit 2, and higher quality of life at visits 1 and 2, which was consistent with adaptive responses of healthy individuals. In the control group, statistically significant changes in these parameters were not observed. In both groups, MDA level was increased during hot weather (р<0.05); however the MDA / SOD ratio characterizing the blood «oxidative potential» was significantly increased only in the control group during summer heat. Conclusion. Mildronate can be used as an adaptogen in patients with moderate and high risk of cardiovascular complications during summer heat.
  1. Терещенко С. Н., Ускач Т. М., Косицина И. В. и др. Особенности сердечно-сосудистых заболеваний и их лечение у женщин. Кардиология.. 2006;46 (1):98–102.
  2. Методология комплексной оценки факторов риска ИБС у женщин. Сердце. 2006;5 (7):336–339.
  3. Архипова Л. В., Гуревич М. А. Особенности ишемической болезни сердца в женской популяции. Актуальные вопросы болезни сердца и сосудов. 2011;1:55–57.
  4. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика. 2008;6 (приложение 4):40 с.
  5. Беленков Ю. Н., Терновой С. К. Функциональная диагностика сердечно-сосудистых заболеваний. – М.: Изд-во «ГЭОТАР-Медиа», 2007. – 976 с.
Smirnova M. D., Svirida O. N., Vitsenya M. V. et al. Use of mildronate for improving adaptation to extreme climatic conditions (heat exposure) in patients with moderate and high risk of cardiovascular complications. Russian Heart Journal. 2013;12(3):186-193

To access this material please log in or register

Register Authorize
Ru En